Journal of the American Academy of Dermatology

The most recent articles from: J. Am. Acad. Dermatol. January 2019

J. Am. Acad. Dermatol. · Jan 2019

Randomized Controlled Trial Comparative Study

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile. ⋯ Compared with ustekinumab, ixekizumab showed superior efficacy and comparable safety outcomes through 52 weeks of treatment.

read on… or not…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.